<DOC>
	<DOCNO>NCT03094416</DOCNO>
	<brief_summary>This open-label therapeutic efficacy study Tirosint ( levothyroxine sodium ) capsule thyroidectomized patient take proton pump inhibitor levothyroxine , evaluate change serum level TSH upon switch Tirosint respect baseline .</brief_summary>
	<brief_title>Levothyroxine Sodium Thyroidectomized Patients Taking Proton Pump Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Hypothyroidism</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>1. write informed consent duly read , sign date subject ; 2. age ≥18 ≤65 year ; 3. history hypothyroidism due total thyroidectomy ; 4. stable LT4 dose least 6 week screen ( ≥88 mcg daily ≤250 mcg daily ) ; 5 . TSH screen ≥0.3 ≤4.0 mIU/L ; 6. history gastroesophageal reflux disease associate gastrointestinal issue prescription PPIs ( i.e . omeprazole ≥20 mg daily , esomeprazole ≥ 20 mg daily , lansoprazole ≥ 15 mg daily , pantoprazole ≥ 40 mg daily ) least 8 week screen visit chronic therapy PPIs next 5 month prescribe ; 7. woman , adequate continuative contraceptive measure end study , menopause ; 8. reasonable assumption understand study willingness take part study comply protocol requirement . 1. suspect ascertained noncompliance LT4 PPI therapy ; 2. subject require change levothyroxine dose ; 3. use overthecounter ( OTC ) PPIs ; 4. history malabsorption history gastric bypass surgery , shortgut syndrome , inflammatory bowel disease condition gastrointestinal tract may affect drug absorption ( e.g . celiac disease ) 3 ; 5. multiple comorbidities ( e.g . cardiac heart failure , active arrhythmia history arrhythmia , particularly atrial fibrillation , uncompensated diabetes mellitus , uncorrected adrenal insufficiency , seriously compromise hepatic , renal and/or respiratory function ) ; 6. neoplastic pathology , active remission le 5 year ( exclude basic thyroid pathology ) ; 7. terminal condition ; 8. parenteral assist enteral feeding ; 9. presence medical condition circumstance would significantly affect safety subject decrease chance obtain reliable data , achieve study objective complete study ; 10. history alcoholism , drug abuse psychiatric disease could invalidate informed consent limit subject compliance protocol requirement ; 11. pregnant ( positive urine pregnancy test screen baseline visit ) breastfeed subject subject planning pregnancy next month ; 12. know hypersensitivity ingredient preparation involve study3 ; 13. use forbidden concomitant medication ; 14. regular consumption soy soy derivative , cotton seed meal , walnut , dietary fibre ; 15. participation clinical study 3 month prior screen ; 16. presumption poor reliability/cooperation ; 17. reason , opinion Investigator , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>